Repros Therapeutics Inc (NASDAQ:RPRX) submitted Form 10-Q wherein it stated that total revenues and other income dropped to $7,000 for the quarter closed June 30, 2017 versus $15,000 for the same quarter in the comparable period, a year ago.
Total revenues and other income dropped to $14,000 for the six-month period closed June 30, 2017 versus $31,000 for the comparable period in the preceding year. The drop in revenues and other income in these periods is mainly due to lower cash balances during the quarter and six-month periods closed June 30, 2017 as against the comparable periods in the preceding year.
The details
Repros stated that R&D expenses comprise contracted services pertaining to their clinical product development activities which comprise preclinical trials, clinical studies, expenses related with company’s patent portfolio, regulatory affairs, counting FDA submission fees, and bulk production scale-up plans and bulk active ingredient purchases for clinical and preclinical trials mainly relating to their two offerings in clinical development, which are enclomiphene and Proellex®.
Research and development expenses even comprise internal operating expenses pertaining to their general research and development measures. R&D expenses dropped 65% to $1.1 million for the quarter closed June 30, 2017 versus $3.2 million for the quarter in the previous year.
Repros reported that the clinical development expenses pertaining to Proellex® dropped for the quarter closed June 30, 2017, versus the prior year period, following decreased expenses related with the company’s Phase 2b clinical studies for the treatment of endometriosis and uterine fibroids.
The clinical development expenses pertaining to enclomiphene dropped for the reported quarter as against the prior year period, due to lower expenses related with its Phase II proof of concept trial, ZA-205. R&D expenses dropped 54% to $3.2 million for the six-month period closed June 30, 2017, as against $7 million for the same semester in the prior year.
